• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒Omicron变异株亚型XBB的流行特征及其科学防控

邓洁 刘民 刘珏

邓洁, 刘民, 刘珏. 新型冠状病毒Omicron变异株亚型XBB的流行特征及其科学防控[J]. 中华疾病控制杂志, 2024, 28(2): 203-208. doi: 10.16462/j.cnki.zhjbkz.2024.02.012
引用本文: 邓洁, 刘民, 刘珏. 新型冠状病毒Omicron变异株亚型XBB的流行特征及其科学防控[J]. 中华疾病控制杂志, 2024, 28(2): 203-208. doi: 10.16462/j.cnki.zhjbkz.2024.02.012
DENG Jie, LIU Min, LIU Jue. Epidemiological feature and scientific prevention and control of SARS-CoV-2 Omicron subvariant XBB[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(2): 203-208. doi: 10.16462/j.cnki.zhjbkz.2024.02.012
Citation: DENG Jie, LIU Min, LIU Jue. Epidemiological feature and scientific prevention and control of SARS-CoV-2 Omicron subvariant XBB[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(2): 203-208. doi: 10.16462/j.cnki.zhjbkz.2024.02.012

新型冠状病毒Omicron变异株亚型XBB的流行特征及其科学防控

doi: 10.16462/j.cnki.zhjbkz.2024.02.012
基金项目: 

北京市自然科学基金-海淀原始创新联合基金 L222027

详细信息
    通讯作者:

    刘珏,E-mail:jueliu@bjmu.edu.cn

  • 中图分类号: R373.1

Epidemiological feature and scientific prevention and control of SARS-CoV-2 Omicron subvariant XBB

Funds: 

Beijing Natural Science Foundation-Haidian Original Innovation Joint Fund L222027

More Information
  • 摘要: 目前新型冠状病毒感染仍处于全球大流行状态,Omicron变异株仍是全球优势株,在流行过程中不断进化和变异出现了许多新的亚型。XBB是由Omicron变异株BA.2.10.1和BA.2.75重组而成,于2022年8月在印度首次被发现,此后迅速传播并成为新加坡、马来西亚及一些欧美国家的主要流行株,并演变出XBB.1、XBB.1.5等亚分支。与Omicron变异株其他亚型相比,XBB的免疫逃逸能力显著增强,但目前尚无证据表明XBB感染所致的疾病严重程度与Omicron其他亚型有差异。建议加强病毒变异监测、开展重点人群疫苗加强针接种、加速疫苗和药物研发、开展多源监测动态评估风险,及时采取科学防控措施,减少XBB毒株的威胁。
  • [1] World Health Organization. WHO coronavirus (COVID-19) dashboard [EB/OL]. (2023-02-14) [2023-02-15]. https://covid19.who.int.
    [2] World Health Organization. Tracking SARS-CoV-2 variants [EB/OL]. (2023-01-04) [2023-01-04]. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
    [3] World Health Organization. Weekly epidemiological update on COVID-19 - 8 February 2023 [EB/OL]. (2023-02-08) [2023-02-16]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-february-2023.
    [4] 廖春晓, 王波, 吕筠, 等. 新型冠状病毒Omicron变异株病原学及流行病学研究进展[J]. 中华流行病学杂志, 2022, 43(11): 1691-1698. DOI: 10.3760/cma.j.cn112338-20220929-00829.

    Liao CX, Wang B, Lyu J, et al. Progress in research of etiology and epidemiology of 2019-nCoV Omicron variant [J]. Chin J Epidemiol, 2022, 43(11): 1691-1698. DOI: 10.3760/cma.j.cn112338-20220929-00829.
    [5] Singh P, Sharma K, Shaw D, et al. Mosaic recombination inflicted various SARS-CoV-2 lineages to emerge into novel virus variants: a review update [J]. Indian J Clin Biochem, 2022: 1-8. DOI: 10.1007/s12291-022-01109-w.
    [6] GISAID. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally over the past 6 months [EB/OL]. (2023-01-03) [2023-01-03]. https://gisaid.org/phylodynamics/global/nextstrain/.
    [7] World Health Organization. TAG-VE statement on Omicron sublineages BQ. 1 and XBB [EB/OL]. (2022-10-27) [2023-01-03]. https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-Omicron-sublineages-bq.1-and-xbb.
    [8] Uraki R, Ito M, Furusawa Y, et al. Humoral immune evasion of the Omicron subvariants BQ. 1.1 and XBB [J]. Lancet Infect Dis, 2023, 23(1): 30-32. DOI: 10.1016/S1473-3099(22)00816-7.
    [9] Wang Q, Iketani S, Li ZT, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants [J]. Cell, 2023, 186(2): 279-286. e8. DOI: 10.1016/j.cell.2022.12.018.
    [10] Wong C. Subvariant ′soup′ may drive wave [J]. New Sci, 2022, 256(3411): 11. DOI: 10.1016/s0262-4079(22)01970-4.
    [11] World Health Organization. Weekly epidemiological update on COVID-19 - 21 December 2022 [EB/OL]. (2022-12-21) [2023-01-03]. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update---21-december-2022.
    [12] World Health Organization. XBB. 1.5 updated rapid risk assessment, 25 January 2023 [EB/OL]. (2023-01-25) [2023-02-16]. https://www.who.int/docs/default-source/coronaviruse/25012023xbb.1.pdf?sfvrsn=c3956081_1.
    [13] American Centers for Disease Control and Prevention. COVID data tracker [EB/OL]. (2023-02-11) [2023-02-16] https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
    [14] American Centers for Disease Control and Prevention. COVID-19 data tracker weekly review [EB/OL]. (2023-01-02) [2023-01-03]. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/.
    [15] European Centre for Disease Prevention and Control. Country overview report: week 5 2023 [EB/OL]. (2023-02-09) [2023-02-16]. https://www.ecdc.europa.eu/en/covid-19/country-overviews?etrans=zh.
    [16] 中华人民共和国国家卫生健康委员会宣传司. 国务院联防联控机制2022年12月20日新闻发布会文字实录[EB/OL]. (2022-12-20) [2023-01-03]. http://www.nhc.gov.cn/xcs/s3574/202212/a9510969ad85461297016f6ad1c87770.shtml.
    [17] 环球网. 国内三地已监测到XBB毒株!有何症状?如何应对?重要提醒[EB/OL]. (2023-01-03) [2023-01-03]. https://baijiahao.baidu.com/s?id=1753956976992201683&wfr=spider&for=pc.
    [18] Outbreak. Info. SARS-CoV-2 (hCoV-19) mutation reports lineage comparison [EB/OL]. (2023-01-03) [2023-01-03]. https://outbreak.info/compare-lineages.
    [19] Scarpa F, Sanna D, Azzena I, et al. Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages [J]. J Med Virol, 2023, 95(3): e28625. DOI: 10.1002/jmv.28625.
    [20] Focosi D, McConnell S, Casadevall A. The Omicron variant of concern: diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies [J]. Drug Resist Updat, 2022, 65: 100882. DOI: 10.1016/j.drup.2022.100882.
    [21] Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ. 1.1 and XBB [J]. N Engl J Med, 2023, 388(1): 89-91. DOI: 10.1056/NEJMc2214302.
    [22] Cao YL, Jian FC, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution [J]. Nature, 2023, 614(7948): 521-529. DOI: 10.1038/s41586-022-05644-7.
    [23] Singapore Ministry of Health. Update on COVID-19 situation and measures to protect healthcare capacity [EB/OL]. (2022-10-15) [2023-01-04]. https://www.moh.gov.sg/news-highlights/details/update-on-covid-19-situation-and-measures-to-protect-healthcare-capacity.
    [24] Singapore Ministry of Health. Moh statement in response to XBB falsehoods [EB/OL]. (2022-10-11) [2023-01-04]. https://www.moh.gov.sg/news-highlights/details/moh-statement-in-response-to-xbb-falsehoods.
    [25] Singapore Ministry of Health. Opening remarks by minister for health mrongye kung at the moh press conference to update on the COVID-19 situation on 15 october 2022 [EB/OL]. (2022-10-15) [2023-01-04]. https://www.moh.gov.sg/news-highlights/details/opening-remarks-by-minister-for-health-mr-ong-ye-kung-at-the-moh-press-conference-to-update-on-the-covid-19-situation-on-15-october-2022.
    [26] Kurhade C, Zou J, Xia HJ, et al. Low neutralization of SARS-CoV-2 Omicron BA. 2.75.2, BQ. 1.1 and XBB. 1 by parental mRNA vaccine or a BA. 5 bivalent booster [J]. Nat Med, 2023, 29(2): 344-347. DOI: 10.1038/s41591-022-02162-x.
    [27] Zou J, Kurhade C, Patel S, et al. Improved neutralization of Omicron BA. 4/5, BA. 4.6, BA. 2.75.2, BQ. 1.1, and XBB. 1 with bivalent BA. 4/5 vaccine [J]. bioRxiv, 2022.11.17.516898. DOI: 10.1101/2022.11.17.516898.
    [28] Sullivan DJ, Franchini M, Senefeld JW, et al. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ. 1.1 and XBB. 1 [J]. J Gen Virol, 2023, 104(5): 001854. DOI: 10.1099/jgv.0.001854.
    [29] Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines [J]. J Med Virol, 2022, 94(5): 1825-1832. DOI: 10.1002/jmv.27588.
    [30] Callaway E. What Omicron′s BA. 4 and BA. 5 variants mean for the pandemic [J]. Nature, 2022, 606(7916): 848-849. DOI: 10.1038/d41586-022-01730-y.
    [31] 中华人民共和国国家卫生健康委员会. 关于印发对新型冠状病毒感染实施"乙类乙管"总体方案的通知[EB/OL]. (2022-12-26) [2023-01-03]. http://www.nhc.gov.cn/xcs/zhengcwj/202212/e97e4c449d7a475794624b8ea12123c6.shtml.
    [32] Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial [J]. Lancet Infect Dis, 2022, 22(8): 1131-1141. DOI: 10.1016/S1473-3099(22)00271-7.
    [33] Romero-Ibarguengoitia ME, González-Cantú A, Rivera-Salinas D, et al. Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine in health workers in Mexico, a pilot study [J]. Vaccines (Basel), 2022, 10(7): 1139. DOI: 10.3390/vaccines10071139.
    [34] Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study [J]. BMJ, 2022, 379: e072141. DOI: 10.1136/bmj-2022-072141.
    [35] Intawong K, Chariyalertsak S, Chalom K, et al. Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and Omicron predominance in Thailand: a test-negative, case-control study [J]. Lancet Reg Health Southeast Asia, 2023, 10: 100121. DOI: 10.1016/j.lansea.2022.100121.
    [36] Kim YY, Choe YJ, Kim J, et al. Effectiveness of second mRNA COVID-19 booster vaccine in immunocompromised persons and long-term care facility residents [J]. Emerg Infect Dis, 2022, 28(11): 2165-2170. DOI: 10.3201/eid2811.220918.
    [37] Grewal R, Nguyen L, Buchan SA, et al. Effectiveness and duration of protection of a fourth dose of coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada [J]. J Infect Dis, 2023, 227(8): 977-980. DOI: 10.1093/infdis/jiac468.
    [38] Kislaya I, Machado A, Magalhães S, et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA. 5 circulation: cohort study based on electronic health records, Portugal, May to July 2022 [J]. Eurosurveillance, 2022, 27(37). DOI: 10.2807/1560-7917.es.2022.27.37.2200697.
    [39] 中国疾病预防控制中心. 关于XBB. 1.5毒株, 这些知识您需要了解[EB/OL]. (2023-01-04) [2023-02-15]. https://mp.weixin.qq.com/s/A11xGdJzhz4ERx9QxEDpow.
  • 加载中
计量
  • 文章访问数:  29
  • HTML全文浏览量:  9
  • PDF下载量:  2
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-02-17
  • 修回日期:  2023-05-07
  • 网络出版日期:  2024-03-30
  • 刊出日期:  2024-02-10

目录

    /

    返回文章
    返回